Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine

Antiviral Research

Volumn 34, Issue 1, 1997, Pages 51-63

  Chong, Kong Teck ^a   Pagano, Paul J ^a  

^a PFIZER INC   (United States)

Author keywords

Delavirdine; Drug combination; HIV 1; Reverse transcriptase inhibitors

Indexed keywords

DELAVIRDINE; DIDANOSINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DELAVIRDINE; DIDANOSINE; DNA, VIRAL; HIV-1; HUMANS; INDOLES; PIPERAZINES; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031000763     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(96)01021-2     Document Type: Article

References (42)

1. Arts, E.J. and Wainberg, M.A. (1996) Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 40 (3), 527-540.
2. Ball, J.K., Holmes, E.C., Whitwell, H. and Desselberger, U. (1994) Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy. J. Gen. Virol. 75, 867-879.
3. Balzarini, J., Karlsson, A., Vandamme, A-M. et al. (1993a) Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-0-(tert-butyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)]-β- D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90, 6952-6956.
4. Balzarini, J., Karlsson, A., Pérez-Pérez, M-J., Camarasa, M-J. and De Clercq, E. (1993b) Knocking-out concentrations of HIV-1 specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 196, 576-585.
5. Balzarini, J., Pelemans, H., De Clercq, E., Camarasa, M.-J. and Karlsson, A. (1995) Structural and functional implications of RT inhibitor resistance. 4th Int. HIV Drug Resistance Workshop, Sardinia, Italy, June 9-11.
6. Belen'kii, M.S. and Schinazi, R.F. (1994) Multiple drug effect analysis with confidence interval. Antiviral Res. 25, 1-11.
7. Caliendo, A.M. and Hirsch, M.D. (1994) Combination therapy for HIV-1 infection. Clin. Infect. Dis. 18, 516-524.
8. Chong, K.T., Pagano, P.J. and Hinshaw, R.R. (1994) Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob. Agents Chemother. 38, 288-293.
9. Chou, T-C. and Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Reg. 22, 27-55.
10. Chow, Y.K., Hirsch, M.S., Merrill, D.P. et al. (1993) Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361, 650-654.
11. D'Aquila, R., Hughes, M. and Liou, S-H. (1995) A comparative study of a combination of zidovudine, didanosine, and double-blinded nevirapine versus a combination of zidovudine and didanosine. 2nd Nat. Conf. on Human Retroviruses, Washington, D.C., Abstract No. 384.
12. Davey, R.T., Chaitt, D.G., Freimuth, W.W., et al. (1995) A randomized phase I/II trial of delavirdine (U-90152S) compared to combination nucleoside therapy in HIV-1 infection. 2nd Nat. Conf. on Human Retroviruses and Related Infections, Washington, D.C., January 29th-February 2nd, Abstract No. 267.
13. De Clercq, E. (1994a) HIV resistance to reverse transcriptase inhibitors. Biochem. Pharm. 47, 155-169.
14. De Clercq, E. (1994b) Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Exp. Opin. Invest. Drugs 3 (3), 253-271.
15. de Jong, M.D., Boucher, C.A.B., Galasso, G.J. et al. (1996) Consensus symposium on combined antiviral therapy. Antiviral Res. 29, 5-29.
16. Dueweke, T.J., Poppe, S.M., Romero, D.L. et al. (1993) U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37, 1127-1131.
17. Freimuth, W.W., Davey, R., Batts, D.H., et al. (1994) Phase II clinical trials of delavirdine mesylate combination therapy. 10th Int. Conf. on AIDS, Yokohama, Japan, August 7-12, Abstract 512B, Vol. 2, p. 59.
18. Freimuth, W.W., Chuang-Stein, C.J., Greenwald, C.A. et al. (1996a) Delavirdine (DLV) and didanosine (ddI) combination therapy has sustained surrogate marker response in advanced HIV-1 population. 3rd Conf. on Retroviruses and Opportunistic Infections, Washington, D.C., Abstract LB8b.
19. Freimuth, W.W., Wathen, L.K., Cox, S.R. et al. (1996b) Delavirdine (DLV) in combination with Zidovudine (ZDV) causes sustained antiviral and immunological effects in HIV-1 infected individuals. 3rd Conf. on Retroviruses and Opportunistic Infections, Washington, D.C., Abstract LB8a.
20. Goodenow, M., Huet, T., Saurin, W., Kwok, S., Sninsky, J. and Wain-Hobson, S. (1989) HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J. Acquired Immune Defic. Syndr. 2, 344-352.
21. Groenink, M., Fouchler, R.A.M., de Goede, R.E.Y., de Wolf, F., Gruters, R.A. and Cuypers, T.M. (1991) Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J. Virol. 65, 1968-1975.
22. Hammer, S.C., Kessler, H.A. and Saag, M.S. (1994) Issues in combination antiretroviral therapy: A review. J. Acquired Immune Defic. Syndr. 7 (Suppl. 2), S24-S37.
23. Johnson, V.A. (1994) Combination therapy: more effective control of HIV Type 1? AIDS Res. Hum. Retroviruses 10, 907-912.
24. Koyanagi, Y., Miles, S., Mitsuyasu, RT., et al. (1987) Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236, 819-822.
25. Kozal, M.J., Shah, N., Yang, R. et al. (1995) Natural polymorphism of HIV-1 clade B protease gene and the implication for therapy. 4th Int. HIV Drug Resistance Workshop, Sardinia, Italy, June 9-11, Abstract 76.
26. Larder, B.A. (1992) 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to non-nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36 (12), 2664-2669.
27. Mazzulli, T., Ruscone, S., Merrill, D.P., et al. (1994) Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob. Agents Chemother. 38, 656-661.
28. Mellors, J.W., Larder, B.A. and Schinazi, R.F. (1995) Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News 3, 8-12.
29. Meyerhans, A.E., Cheynler, R., Albert, J. et al. (1989) Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 58, 901-910.
30. Mohri, H., Singh, M.K., Ching, W.T.W., Ho, D.D. (1993) Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc. Natl. Acad. Sci. USA 90, 25-29.
31. Murphy, R., Havlir, D., Saag, M.S. et al. (1995) Safety, immunologic and virologie activity of nevirapine in combination with zidovudine therapy in HIV-infected patients. 2nd Nat. Conf. on Human Retroviruses, Washington, D.C., Abstract No. 262.
32. Nájera, I., Richman, D.D., Olivares, I. et al. (1994) Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res. Hum. Retroviruses 10, 1479-1488.
33. Nájera, I., Holguin, A., Quiñones-Mateu, M.E. et al. (1995) pol Gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69, 23-31.
34. Pagano, P.J. and Chong, K.T. (1995) In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-α. J. Inf. Dis. 171, 61-67.
35. Richman, D.D. (1996) The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res. 29, 31-33.
36. Rusconi, S. and Merrill, D.P. (1994) Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. J. Infect. Dis. 170, 1361-1366.
37. St. Clair, M.H., Pennington, K.N., Rooney, J. and Barry, D.W. (1995) In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the intercompany collaboration protocol. J. Acquired Defic. Syndr. Hum. Retrovirol. 10 (Suppl. 2), 583-591.
38. Staszewski, S., Miller, V., Rehmet, S. et al. (1994) A triple combination study with zidovudine, lamivudine (3TC) and loviride (R89439) in p24 positive HIV-1 infected patients: an interim analysis. 34th Int. Conf. on Antimicrobial Agents and Chemotherapy, October 4-7, Orlando, FL.
39. Vasudevachari, M.B., Battista, C., Lane, H.C. et al. (1992) Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology 190, 269-277.
40. vonBriesen, H., Becker, W.B., Henko, K. et al. (1987) Isolation frequency and growth properties of HIV-variants: multiple simultaneous variants in a patient demonstrated by molecular cloning. J. Med. Virol. 23, 51-66.
41. Wathen, L.K., Crampton, D.J., Patel, R.K. et al. (1996) Validation of a quantitative RNA PCR assay for HIV-1 in human plasma. J. Clin. Lab. Analy. 10 (5), 262-268.
42. Wei, X., Johnson, V., Taylor, M. et al. (1994) Rapid HIV-1 turnover in patients receiving combination nevirapine (Nev) therapy. 34th Int. Conf. on Antimicrobial Agents and Chemotherapy, October 4-7, Orlando, FL. Abstract No. 164.